LXS 196

Drug Profile

LXS 196

Alternative Names: LXS196

Latest Information Update: 16 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Antineoplastics; Skin disorder therapies
  • Mechanism of Action Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Uveal melanoma

Most Recent Events

  • 01 Feb 2016 Phase-I clinical trials in Uveal melanoma (Metastatic disease, Monotherapy) in Netherlands (PO) (NCT02601378)
  • 30 Nov 2015 Novartis plans a phase I trial in Uveal melanoma (Metastatic disease, Monotherapy) in USA, France, Spain, Australia and Netherlands (NCT02601378)
  • 01 Nov 2015 Preclinical trials in Uveal melanoma in USA (PO) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top